ViGeneron Announces FDA Rare Pediatric Disease Designation for VG901 and DSMB Approval to Advance Dose Escalation in Phase 1b Retinitis Pigmentosa Trial
. VG901 is the first-in-class and only clinical-stage therapy designed to deliver the functional CNGA1 gene intravitr…